KR20230107211A - 신경학적 질환 및 장애를 개선하기 위한 조성물 및 방법 - Google Patents

신경학적 질환 및 장애를 개선하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230107211A
KR20230107211A KR1020237010888A KR20237010888A KR20230107211A KR 20230107211 A KR20230107211 A KR 20230107211A KR 1020237010888 A KR1020237010888 A KR 1020237010888A KR 20237010888 A KR20237010888 A KR 20237010888A KR 20230107211 A KR20230107211 A KR 20230107211A
Authority
KR
South Korea
Prior art keywords
agent
pabra
dose
blocker
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010888A
Other languages
English (en)
Korean (ko)
Inventor
안토니 피. 포드
가브리엘 바르가스
웨이 첸
르네 에스. 마틴
Original Assignee
큐라센 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐라센 테라퓨틱스, 인코포레이티드 filed Critical 큐라센 테라퓨틱스, 인코포레이티드
Publication of KR20230107211A publication Critical patent/KR20230107211A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/501—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the head, e.g. neuroimaging or craniography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Dentistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237010888A 2020-09-01 2021-08-31 신경학적 질환 및 장애를 개선하기 위한 조성물 및 방법 Pending KR20230107211A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US63/073,353 2020-09-01
US202163212077P 2021-06-17 2021-06-17
US63/212,077 2021-06-17
PCT/US2021/048540 WO2022051305A1 (en) 2020-09-01 2021-08-31 Compositions and methods for improving neurological diseases and disorders

Publications (1)

Publication Number Publication Date
KR20230107211A true KR20230107211A (ko) 2023-07-14

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010888A Pending KR20230107211A (ko) 2020-09-01 2021-08-31 신경학적 질환 및 장애를 개선하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (1) US20230263749A1 (enExample)
EP (1) EP4208159A4 (enExample)
JP (1) JP2023541379A (enExample)
KR (1) KR20230107211A (enExample)
CN (1) CN116801875B (enExample)
AU (1) AU2021337583A1 (enExample)
CA (1) CA3189243A1 (enExample)
MX (1) MX2023002350A (enExample)
WO (1) WO2022051305A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022185255A1 (en) 2021-03-03 2022-09-09 Lenovo (Singapore) Pte. Ltd. Beam failure detection using multiple sets of reference signals
US20260207568A1 (en) * 2022-12-21 2026-07-23 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
US20250107713A1 (en) * 2023-09-29 2025-04-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Confirming Iboga Alkaloid Treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952101A (en) * 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2018195473A1 (en) * 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
AU2019287771A1 (en) * 2018-06-14 2021-01-28 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
US10947196B2 (en) * 2019-03-27 2021-03-16 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same
US20220401415A1 (en) * 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
JP7734700B2 (ja) * 2020-06-04 2025-09-05 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニストの形態及び組成物

Also Published As

Publication number Publication date
AU2021337583A1 (en) 2023-05-04
EP4208159A1 (en) 2023-07-12
CA3189243A1 (en) 2022-03-10
MX2023002350A (es) 2023-04-26
CN116801875B (zh) 2026-06-05
AU2021337583A9 (en) 2024-06-27
WO2022051305A1 (en) 2022-03-10
CN116801875A (zh) 2023-09-22
US20230263749A1 (en) 2023-08-24
JP2023541379A (ja) 2023-10-02
EP4208159A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US12558325B2 (en) Methods for improving neurological diseases and disorders
EP3806957A1 (en) Methods for diagnosing, monitoring and treating neurological diseases and disorders
CA3100848A1 (en) Methods for improving neurological diseases and disorders
US20160213792A1 (en) Heterocyclic molecules for biomedical imaging and therapeutic applications
US20230263749A1 (en) Compositions and methods for improving neurological diseases and disorders
JP2012507534A (ja) 新規置換アザベンゾオキサゾール類
CN106008374B (zh) 吡嗪类化合物及其在医药上的用途
US20230414588A1 (en) Compositions and methods for treating patients with amyotrophic lateral sclerosis (als)
CA2911307C (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US12616667B2 (en) Compositions and methods for improving neurological diseases and disorders
WO2025188807A1 (en) Combination compositions and methods of use
WO2024137506A1 (en) Compositions and methods for improving neurological diseases and disorders
US20210251923A1 (en) Methods for improving neurological diseases and disorders
WO2024137478A1 (en) Methods for treating various conditions and indications with agonists and antagonists
WO2023250332A1 (en) Compositions and methods involving isolated compounds
CN111253398B (zh) 一种用于检测神经损伤的荧光化合物及其应用
WO2023250334A1 (en) Compositions and methods involving isolated compounds
CN104803993B (zh) 一种具有Aβ亲和力的荧光化合物及其用途
JP2023103293A (ja) 可溶性エポキシドヒドロラーゼ（ｓＥＨ）のＰＥＴイメージング用１８Ｆ－ＦＮＤＰ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230329

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240830

Comment text: Request for Examination of Application